Theme

Futura Medical

FUMHealthcare
8.83GBX
1.15%
Market Cap
26.85M
Volume
5.77k
1% of avg
P/E Ratio
4.05
EPS (TTM)
2.18
Beta
0.65
Day Range
0.00p - 0.00p
52 Week Range
0.00p8.83p40.95p
8.83p

Upcoming Events

Late September 2025
Interim results publication
High Impact Event
End of 2025
Regulatory approval for Eroxon® Intense expected in EU & USA
High Impact Event
Early Q2 2026
Completion of Early Feasibility Study for WSD4000
FUM
NEUTRAL

Futura Medical Provides Business Update, Announces Interim Results

The healthcare company announces board changes and a review of its business and commercial plans for its lead product Eroxon.

FUM
NEUTRAL

Futura Medical Provides Update on Share Price Movement

The healthcare company provides an update on its recent share price movement, noting the increase but stating it knows of no specific reason for the rise.

FUM
NEUTRAL

Futura Medical Announces Board Changes

The consumer healthcare group behind Eroxon® announces changes to its Board of Directors, with the CEO and Chair stepping down and an interim CEO being appointed.

FUM
NEUTRAL

Futura Medical Announces AGM and Availability of Annual Report

The healthcare company announces its upcoming Annual General Meeting and the availability of its annual report.

FUM
NEUTRAL

Futura Medical Appoints New Broker

The healthcare company has appointed a new broker to act as its sole broker and continue as Nominated Adviser.

FUM
BAD

Futura Medical Reports First Profit, But Warns of Slower Growth Ahead

The healthcare company reported its maiden profit and significant revenue growth, but warned of slower expansion and launch delays, impacting future performance expectations.

FUM
NEUTRAL

Futura Medical Announces Results and Investor Presentation

The healthcare company will announce its annual results and host investor presentations next month.

FUM
NEUTRAL

Futura Medical Appoints New Non-Executive Director

The healthcare company has appointed a new Non-executive Director with investment management experience.

FUM
BAD

Futura Medical Slashes FY25 Forecast Despite Strong FY24 Performance

The healthcare company reported strong FY24 results but drastically lowered FY25 expectations due to slower product adoption. A shift from anticipated profits to projected losses in FY25 has overshadowed the positive performance.

FUM
NEUTRAL

Futura Medical Announces Positive Results for Women's Sexual Dysfunction Treatment

The healthcare company reports successful completion of a study for its women's sexual dysfunction treatment, paving the way for further development.